季节性冠状病毒感染个体中 SARS-CoV-2 感染和 COVID-19 严重程度。
SARS-CoV-2 infection and COVID-19 severity in individuals with prior seasonal coronavirus infection.
机构信息
Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Department of Biomedical Informatics and Medical Education, University of Washington School of Medicine, Seattle, WA, USA.
出版信息
Diagn Microbiol Infect Dis. 2021 Jun;100(2):115338. doi: 10.1016/j.diagmicrobio.2021.115338. Epub 2021 Feb 9.
Abstract
We show that individuals with documented history of seasonal coronavirus have a similar SARS-CoV-2 infection rate and COVID-19 severity as those with no prior history of seasonal coronavirus. Our findings suggest prior infection with seasonal coronavirus does not provide immunity to subsequent infection with SARS-CoV-2.
摘要
我们的研究表明，有季节性冠状病毒病史的个体与没有季节性冠状病毒病史的个体 SARS-CoV-2 感染率和 COVID-19 严重程度相似。我们的研究结果表明，先前感染季节性冠状病毒并不能为随后感染 SARS-CoV-2 提供免疫力。
相似文献
1
SARS-CoV-2 infection and COVID-19 severity in individuals with prior seasonal coronavirus infection.
Diagn Microbiol Infect Dis. 2021 Jun;100(2):115338. doi: 10.1016/j.diagmicrobio.2021.115338. Epub 2021 Feb 9.
2
Antibodies to Seasonal Coronaviruses Rarely Cross-React With SARS-CoV-2: Findings From an African Birth Cohort.
Pediatr Infect Dis J. 2021 Dec 1;40(12):e516-e519. doi: 10.1097/INF.0000000000003325.
3
Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses.
Cell Rep. 2021 Dec 28;37(13):110169. doi: 10.1016/j.celrep.2021.110169. Epub 2021 Dec 7.
4
Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19.
J Clin Invest. 2021 Nov 1;131(21). doi: 10.1172/JCI150613.
5
Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses.
J Infect Dis. 2021 Jul 2;224(1):49-59. doi: 10.1093/infdis/jiab161.
6
Potential impact of individual exposure histories to endemic human coronaviruses on age-dependent severity of COVID-19.
BMC Med. 2021 Jan 12;19(1):19. doi: 10.1186/s12916-020-01887-1.
7
Limited Recognition of Highly Conserved Regions of SARS-CoV-2.
Microbiol Spectr. 2022 Feb 23;10(1):e0278021. doi: 10.1128/spectrum.02780-21.
8
Prior presumed coronavirus infection reduces COVID-19 risk: A cohort study.
J Infect. 2020 Dec;81(6):923-930. doi: 10.1016/j.jinf.2020.10.023. Epub 2020 Oct 27.
9
Seasonal coronavirus protective immunity is short-lasting.
Nat Med. 2020 Nov;26(11):1691-1693. doi: 10.1038/s41591-020-1083-1. Epub 2020 Sep 14.
10
Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination.
J Virol. 2023 Mar 30;97(3):e0166422. doi: 10.1128/jvi.01664-22. Epub 2023 Feb 13.
引用本文的文献
1
Differential patterns of antibody response against SARS-CoV-2 nucleocapsid epitopes detected in sera from patients in the acute phase of COVID-19, convalescents, and pre-pandemic individuals.
Pathog Dis. 2024 Feb 7;82. doi: 10.1093/femspd/ftae025.
2
Does Prior Respiratory Viral Infection Provide Cross-Protection Against Subsequent Respiratory Viral Infections? A Systematic Review and Meta-Analysis.
Viruses. 2024 Jun 19;16(6):982. doi: 10.3390/v16060982.
3
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents.
iScience. 2023 Nov 21;26(12):108500. doi: 10.1016/j.isci.2023.108500. eCollection 2023 Dec 15.
4
The role of cross-reactive immunity to emerging coronaviruses: Implications for novel universal mucosal vaccine design.
Saudi Med J. 2023 Oct;44(10):965-972. doi: 10.15537/smj.2023.44.10.20230375.
5
Unravelling Antigenic Cross-Reactions toward the World of Coronaviruses: Extent of the Stability of Shared Epitopes and SARS-CoV-2 Anti-Spike Cross-Neutralizing Antibodies.
Pathogens. 2023 May 13;12(5):713. doi: 10.3390/pathogens12050713.
6
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors.
Viruses. 2023 Jan 7;15(1):175. doi: 10.3390/v15010175.
7
Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms.
Vaccines (Basel). 2022 Dec 27;11(1):58. doi: 10.3390/vaccines11010058.
8
Pre-Pandemic Cross-Reactive Immunity against SARS-CoV-2 among Central and West African Populations.
Viruses. 2022 Oct 14;14(10):2259. doi: 10.3390/v14102259.
9
Knowledge of SARS-CoV-2 Epitopes and Population HLA Types Is Important in the Design of COVID-19 Vaccines.
Vaccines (Basel). 2022 Sep 24;10(10):1606. doi: 10.3390/vaccines10101606.
10
Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination.
Front Immunol. 2022 Oct 6;13:942192. doi: 10.3389/fimmu.2022.942192. eCollection 2022.
本文引用的文献
1
Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4 T Cells in COVID-19.
Cell. 2020 Nov 25;183(5):1340-1353.e16. doi: 10.1016/j.cell.2020.10.001. Epub 2020 Oct 5.
2
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.
Science. 2020 Oct 2;370(6512):89-94. doi: 10.1126/science.abd3871. Epub 2020 Aug 4.
3
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.
Nature. 2020 Nov;587(7833):270-274. doi: 10.1038/s41586-020-2598-9. Epub 2020 Jul 29.
4
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.
Nature. 2020 Aug;584(7821):457-462. doi: 10.1038/s41586-020-2550-z. Epub 2020 Jul 15.
5
Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome.
Sci Immunol. 2020 Jun 26;5(48). doi: 10.1126/sciimmunol.abd2071.
6
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
Cell. 2020 Jun 25;181(7):1489-1501.e15. doi: 10.1016/j.cell.2020.05.015. Epub 2020 May 20.
Zotero 插件